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Abstract
Introduction: The C677T MTHFR variant has been associated with the same third trimester
pregnancy complications as seen in women who have elevations of maternal serum α-fetoprotein
(MSAFP). We hypothesized that these women with third trimester pregnancy complications and
MSAFP elevations would have an increased frequency of the variant compared to an abnormal
study control group (women with MSAFP elevations without pregnancy complications) as well as
to normal population controls.
Methods: Women who had unexplained elevations of MSAFP in pregnancy were ascertained
retrospectively. The frequency of the C677T MTHFR variant among those women with
unexplained elevations of MSAFP who had experienced later pregnancy complications was
compared to that of women with unexplained elevations of MSAFP without complications as well
as to that of the previously established Manitoba frequency.
Results: Women who had complications of pregnancy and an unexplained MSAFP elevation had a
higher allele frequency for the C677T MTHFR variant (q = 0.36,) compared to women with MSAFP
elevations and normal pregnancy outcomes (q = 0.25, OR 1.73 95% CI 1.25–2.37, p = 0.03). The
frequency was also higher than that of the population controls (q= 0.25, OR 1.70 95% CI 1.11–2.60,
p = 0.007). The frequency in women with MSAFP elevations without pregnancy complications was
not significantly different from that of the population controls (p = 0.41).
Conclusion: Women with unexplained elevations of MSAFP and who experience complications
in later pregnancy are more likely to have one or two alleles of the C677T MTHFR variant.
Background
Significant elevations of amniotic fluid and maternal
serum alpha-fetoprotein (MSAFP) have been shown to be
associated with spina bifida and other neural tube defects
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(NTD). The province of Manitoba, Canada offers prov-
ince-wide midtrimester MSAFP screening to all pregnant
women. It has been recognized that some pregnant
women with midtrimester unexplained elevations of
MSAFP [1,2].
Increased total plasma homocysteine alters placental
function and has been associated with the same complica-
tions that are associated with unexplained elevated
MSAFP [3-7]. The C677T MTHFR variant has also been
associated with complications of pregnancy in some, but
not all, studies [8-10] C677T MTHFR may therefore con-
tribute to complications of pregnancy by elevating serum
homocysteine. Poor placental function could result in
both an unexplained elevation of MSAFP and complica-
tions of pregnancy. We therefore hypothesized that
women with third trimester pregnancy complications and
MSAFP elevations (cases) would have an increased fre-
quency of the variant compared to the Manitoba popula-
tion (population controls) or women with MSAFP
elevations without pregnancy complications (study con-
trols) if they had low folate intake.
Methods
Background to methods
In a small pilot study of 32 couples, we found that women
who had an unexplained elevation of MSAFP and a nor-
mal midtrimester fetal ultrasound, and their partners, had
a significantly increased C677T MTHFR frequency com-
pared to Manitoba newborns (RR 1.42, 95% CI 1.08–
1.85, p = 0.012, two tailed) [11]. The newborn study that
examined 977 anonymous consecutive neonatal screen-
ing blood spots showed that 36% of Manitoba newborns
were heterozygous and 7% were homozygous for C677T
MTHFR [12] (q = 0.25). Subsequently, on evaluation of
the pregnancy outcomes of our pilot study women, we
noted that, among eight women who had gone on to
experience complications of pregnancy, the odds ratio for
having the C677T MTHFR allele was 2.3 times higher than
in the Manitoba population. However, the result was not
statistically significant (p = 0.151, two tailed) indicating
the frequency was increased but, this could have been a
random result.
Ascertainment and recruitment of study population
All pregnant women in Manitoba are eligible for routine
serum screening through the voluntary MMSSP. In Mani-
toba, an elevation of MSAFP is defined as 2.3 multiples of
the median (MOM) or greater. Candidates for inclusion in
this study were women with an unexplained MSAFP ele-
vation (i.e. not due to fetal anomalies, incorrect estima-
tion of gestational age, previously unrecognized fetal
demise, or multiple gestation) with either a complicated
or uncomplicated pregnancy outcome. After appropriate
approvals had been obtained from The University of
Manitoba Health Research Ethics Board, review of the
screening records began in 1999 and took three years. For
a study using a two step consent to participate methodol-
ogy administered by mail, the expected response rate
(after excluding lost to follow-up) would be 20% [13].
Our goal was 1000 invitations. We anticipated this would
result in approximately 120 participants. This would be
double the minimum number of participants suggested
by the power analysis we had conducted for the pilot
study. To increase our response rate further, we added tel-
ephone follow-up for invited potential participants who
were non-responders [14].
All screening records from 1995–1999 were reviewed,
accounting for 783 invitations. Records for 2000–2002
were reviewed systematically as outcome information on
each pregnancy became available to MMSSP. Records for
1990–1994 were then reviewed systematically in order to
bring the total up to 1000. If a woman had more than one
pregnancy with an elevation of MSAFP screened by the
MMSSP, only the first pregnancy encountered in the retro-
spective review was used for the study. Previous or subse-
quent pregnancies were not included. Women with
preexisting conditions known to influence pregnancy out-
come, such as essential hypertension, and mothers of
babies with major congenital anomalies were excluded.
Eight women who had relinquished their babies for adop-
tion or whose babies were placed in foster care were also
excluded.
Women who met the inclusion criteria were divided into
two groups for analysis. Cases were defined as women
with pregnancies complicated by one of the complica-
tions previously shown to be associated with an unex-
plained elevation of MSAFP at midtrimester [2]. These
include: intrauterine growth restriction (IUGR) (<10th
percentile), pregnancy induced hypertension, preeclamp-
sia, eclampsia, postpartum hemorrhage, retained placenta
requiring manual delivery, abruptio placenta, premature
delivery (<36 weeks gestation or requiring specialized
neonatal care for prematurity) and unexplained fetal
demise. Study controls were women with normal out-
comes which were defined as those with delivery at term
≥ 36 weeks gestation), no complications of pregnancy, a
normal placenta and a healthy baby. Definition of com-
plications was based on ICDC-9 codes in the MMSSP out-
come charts for each patient [15] which are then
confirmed later by chart review for all those with a posi-
tive MMSSP result. All women ascertained as having unex-
plained MSAFP elevations and who fit the inclusion
criteria above, were invited by letter to participate. The
previously reported newborn study provided population
control group data [12].Reproductive Biology and Endocrinology 2004, 2:65 http://www.rbej.com/content/2/1/65
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Study questionnaires
Women who agreed to participate in the study were
mailed the appropriate questionnaires and blood requisi-
tions. The questionnaire included a semi-quantitative
food frequency questionnaire (FFQ) based on standard
methodology but, modified to suit Manitoba residents
and previously validated for this population by biochem-
ical analysis during the pilot study [11,16]. The survey
included questions on vitamin supplement intake to
determine preconceptional or prenatal supplementation
as well as current use of vitamins. Dietary intake of folate
and folic acid from supplements, and intake of the cofac-
tors B12 and B6, were calculated from the FFQ for intake
both during pregnancy and at the time of the study. A cor-
rection of an additional 0.1 mg for folic acid fortification
that began in Canada in 1998 was included for pregnan-
cies that began after fortification [17]. FFQ analyses were
performed with the researcher blinded as to the status of
the mother.
Laboratory analysis
Total plasma homocysteine, red blood cell folate, and
serum folate were determined using established method-
ology [18,19]. Samples were processed on site with clot-
ting and separation by spinning. Sera was stored at 4°C
during shipping to the central laboratory and until
processing. DNA was extracted from whole blood and
C677T MTHFR genotyping was performed using previ-
ously established methodology [11,20,21]. Genotyping
and biochemical analyses were performed also blinded.
Statistical analysis
Chi-squared analysis (one tailed unless otherwise noted)
was used for allele frequency. Comparisons of potentially
confounding factors between the case group and the study
control group were undertaken. Parametric data were ana-
lyzed with the Student's t  test for difference between
means with Bonferroni correction for multiple compari-
sons. Data not normally distributed were analyzed using
the nonparametric Mann-Whitney Rank Sum Test. Linear
regression was used to test the validity of the dietary sur-
vey. A multivariate analysis included age, smoking, mater-
nal weight at the time of MSAFP testing, presence of
C677T MTHFR, gender and weight of infant, biochemical
parameters, and FFQ results for folate, B12 and B6, both at
the time of the survey and for during the pregnancy was
undertaken. In order to avoid convergence due to the large
number of variables, the analysis was completed in sub-
sets of six variables. Variables with the higher association
scores from these analyses were then combined for further
testing in various combinations using stepwise multiple
linear regression. Also linear regression analysis of each
continuous variable with genotype results was performed.
Corrections for multiple comparisons were included.
Software used was NCSS Statistical Systems for Windows
[22].
Results
Participation rates
Nine hundred and ninety four women were identified as
eligible (342 cases and 652 controls). Of the 590 women
successfully contacted, 130 (22%) agreed to participate
(56 cases and 74 controls). Four hundred and four
women were lost to follow-up. Cases were more likely to
choose to participate than controls and this difference was
significant (1.5, p = 0.030). There was no difference in the
proportions of cases and controls that were lost to follow-
up (p = 0.157). We had anticipated a 20% response rate
and we achieved 24%.
Genotype results
Genotypes were available for 54 cases and 73 controls for
this analysis. Results are summarized in Table 1. The allele
frequency for the C677T MTHFR variant in the Manitoba
population has been previously established to be q = 0.25.
Women who had complications of pregnancy and an
unexplained MSAFP elevation had a higher allele fre-
quency for the C677T MTHFR variant (q = 0.36) com-
pared to women with MSAFP elevations and normal
pregnancy outcomes (q = 0.25, OR 1.73 95% CI 1.25–
2.37, p = 0.03). The frequency was also higher than in the
population controls (q = 0.25, OR 1.70 95% CI 1.11–
2.60, p = 0.007). The frequency in women without preg-
nancy complications and MSAFP elevations (study con-
trols) was not significantly different than that seen in
population controls (p = 0.41).
Table 1: Comparison of allele frequency of C677T MTHFR between cases, study controls, and population controls.
Subjects C/C (%) C/T (%) T/T (%) Comparing to study 
controls* OR (95%CI)
Comparing to population* 
OR (95%CI)
Cases N = 54 21 (39) 27 (50) 6 (11) 1.73 (1.25–2.37) (p = 0.033) 1.70 (1.11–2.60) (p = 0.007)
Study Controls N = 73 40 (55) 30 (41) 3 (4) ~ 0.98 (0.46–1.55) (p = 0.410)
Population N = 977 557 (57) 352 (36) 68 (7) 0.98 (0.46–1.55) (p = 0.410) ~
* χ2 comparison of allele frequency (total T and C) in each group, one tailed. Cases: women with unexplained elevations of MSAFP who had 
subsequent complications of pregnancy, (C = 69, T = 39) Controls: women who had unexplained elevations of MSAFP and no subsequent 
complications (C = 110, T = 36) Population controls were 977 newborns (C = 1466, T = 488) [12]. C/C = normal type, C/T = heterozygous for 
thermolabile variant, T/T = homozygous for thermolabile variant.Reproductive Biology and Endocrinology 2004, 2:65 http://www.rbej.com/content/2/1/65
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The case and study control groups included women at var-
ious stages of their child bearing years. Only one woman
recruited as a control subject had a previous or subsequent
pregnancy with an unexplained elevation of MSAFP and
complications. She was a heterozygote for C677T MTHFR.
No case subjects had a previous or subsequent pregnancy
with an unexplained elevation of MSAFP and a normal
outcome, but four case subjects had had a previous or sub-
sequent pregnancy with complications after an elevated
MSAFP. If the case versus control classification had been
based on whether or not a woman had ever had a preg-
nancy with an unexplained elevation of MSAFP followed
by complications, the association would still be present
when compared to the population control (q = 0.3636,
OR 1.72, 95%CI 1.27–2.61, p = 0.0055).
Biochemical results
Heterozygotes and homozygotes for C677T MTHFR had
lower average values (r = 0.978, p = 0.019) for serum
folate than those who did not have the variant. None of
the women were deficient in either serum folate (defined
as <7.0 nmol/L) or red blood cell folate (defined as <430
nmol/L RBC). There was no significant difference in mean
homocysteine levels (Table 2).
Validity of surveys
Seven cases and one study control declined to fill out their
dietary surveys. Mean values were inserted in the multivar-
iate analysis for these eight women. The validity of the
dietary survey was demonstrated again for this study by
linear regression analysis. Consistent with known homo-
cysteine metabolism [23], a negative correlation existed
between serum homocysteine and both red blood cell
folate (r = 0.945 p = 0.0052) and serum folate (r = 0.932,
p = 0.0001). Higher intake of dietary folate (including syn-
thetic folic acid from supplements) as reported by the FFQ
for the time of study was associated with higher serum
folate (r = 0.941, p = 0.0001) and higher red blood cell
folate (r = 0.949, p = 0.0166).
We did several checks to determine that the women were
answering their surveys accurately. Comparisons of spe-
cific data items available in the women's MMSSP charts at
the time of pregnancy with the data reported in the sur-
veys showed excellent agreement for every item examined
indicating women answered questions accurately.
Women who reported smoking (as a quantitative value
from 0–3 based on 1/2 packs/day smoked) showed a neg-
ative correlation with serum folate (r = 0.923, p = 0.0062)
consistent with accurately reporting their smoking habits
[24]. Based on the results of these tests of the validity of
our surveys, we are confident that the information pro-
vided by our participants was accurate.
Analysis of FFQ survey and MMSSP data
The ethnicity of the infants born to the case mothers
(based on the ethnicity reported for the infants grandpar-
ents) was 84% Caucasian, 5% Aboriginal. Mixed ethnicity
was reported for 11% of the infants with one parent Cau-
casian and the other parent Aboriginal, or rarely Black or
Asian. The ethnic distribution was the same for controls
and is typical for the Manitoba population [25,26]. There
Table 2: Comparison of the parametric characteristics of women with unexplained elevations of MSAFP according to those with and 
without complications of pregnancy
Characteristic Mean Cases (SD) Mean Controls (SD) p value
MSAFP result 2.78 (± 0.62) 3.16 (± 3.76) 0.398
weeks gestation 17.1 (± 1.61) 16.9 (± 1.40) 0.432
µg/folate/day in pregnancy2 1216 (± 915) 1010 (± 892) 0.206
µg/folate/day at time of study2 557 (± 341) 523 (± 498) 0.588
erc folate (nmol/L RBC) 1234 (± 289) 1208 (± 317) 0.632
serum folate (nmol/L) 32.3 (± 5.80) 32.3 (± 5.71) 0.956
serum homocysteine (µmol/L) 7.8 (± 2.26) 8.4 (± 2.80) 0.246
µg B12/day in pregnancy2 12.4 (± 5.37) 13.4 (8.31) 0.488
µg B12/day at time of study2 8.9 (± 12.26) 8.6 (± 10.83) 0.899
mg B6/day in pregnancy2 8.4 (± 9.69) 7.2 (± 9.01) 0.461
mg B6/day at time of study2 6.0 (± 13.35) 5.5 (± 11.10) 0.792
mother's age at delivery 31 (± 4.19) 30 (± 5.19) 0.251
mother's weight in Kg 76 (± 17.26) 69 (± 16.09) 0.0131
1 This value is not significant after Bonferroni correction for multiple comparisons. See discussion. 2Data was skewed due to a small number of 
women in both groups taking large dose vitamin supplements. When these women were removed from the analysis the result remained 
nonsignificant.Reproductive Biology and Endocrinology 2004, 2:65 http://www.rbej.com/content/2/1/65
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were also no significant differences between cases and
controls with respect to their place of residence within the
province (such as rural versus urban address).
There were no significant differences in dietary and sup-
plemental intake of folate, B12, or B6, or in the biochemi-
cal parameters of case and control mothers. There was no
difference in the percentage of cases and controls who
reported taking prenatal vitamin supplements during
pregnancy (37/48 cases and 55/72) or taking vitamin
and/or folate supplements preconceptionally (17/48
cases and 25/72 study controls).
We attempted to divide our cases into smaller groups by
type of pregnancy complication. We also separated iso-
lated IUGR and IUGR associated with hypertensive disor-
ders of pregnancy. Most of the groups lacked power for
statistical analysis due to small numbers. However, nor-
motensive women whose fetus had IUGR (N = 12) had a
higher frequency of the C677T MTHFR variant compared
to the population controls (q = 0.33, OR 2.58 95% CI,
1.78–3.73,  p  = 0.013). Homozygosity for the C677T
MTHFR variant is associated with IUGR in women who do
not take vitamin supplements according to one large
study of Canadian women [10,27]. Our findings are in
agreement with this result as only 3/12 women took sup-
plements. We found this effect in a group of combined
heterozygous and homozygous women.
There was a trend towards higher mean weight for moth-
ers who had complications at the time of MSAFP test in
the individual comparisons, but this was not significant
after correction for multiple comparisons (Table 2 and 3).
The multivariate analysis did not reveal any unexpected
associations, but it did show the importance of maternal
weight as a variable (r = 0.933, p = 0.024). This was also
not unexpected given that some of the complications we
were examining are associated with obesity [28]. Even
after controlling for women's weight in the multivariate
analysis, the higher frequency of C677T MTHFR among
cases remained significant (r = 0.734, p = 0.0462). There
was no association between weight and MTHFR status (r
= 0.431, p = 0.679).
Discussion
Unexplained elevations in MSAFP are known to be associ-
ated with an increased risk for complications of pregnancy
[2]. Others have reported that presence of the C677T
MTHFR variant in pregnant women with low folate intake
is associated with increased risk for pregnancy complica-
tions [2,29-31]. The unique finding of this study is an
increase in the frequency of the C677T MTHFR variant
among women with normal folate intake, who went on to
have complications of pregnancy after an unexplained ele-
vation of MSAFP (Table 1).
Table 3: Comparison of the nonparametric characteristics of women with unexplained elevations of MSAFP according to those with 
and without complications of pregnancy.
Nonparametric Characteristics Cases Controls p value
Location
Winnipeg 44 63 0.854
southern city 3 2
southern town 3 5
southern rural 8 8
northern city 2 1
northern town 1 4
northern rural 5 7
ethnicity 0.972
Caucasian 52 66
Aborginal 2 2
Mixed Caucasian/Aboriginal 7 6
Mixed Caucasian/Black 1 3
Asian 1 1
Mixed Caucasian/Asian 1 1
Unknown 3 1
diabetes in pregnancy 2/67 1/80 0.207
maternal smoking present (0 = nonsmoker, 1–3 = half 
pks/day increments)
0 = 47, 1 = 11, 2 or more = 9 0 = 60, 1 = 8, 2 or more = 12 0.721
gender of baby 27 females, 40 males 42 females, 38 males 0.352
parity = number of women 0 = 37, 1 = 20, 2 = 7, 3 or more = 3 0 = 40, 1 = 29, 2 = 7, 3 or more = 4 0.254
previous miscarriages 11/67 15/80 0.203
previous case pregnancy 1 0 0.967Reproductive Biology and Endocrinology 2004, 2:65 http://www.rbej.com/content/2/1/65
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The lack of folate deficiency in this population was unex-
pected, given previous research which showed that 23.6%
of Newfoundland and Labrador women are folate defi-
cient at their first prenatal visit [32]. As our study was ret-
rospective, we did not have data on levels during
pregnancy. It has recently been shown that the C677T
MTHFR variant does not affect maternal serum homo-
cysteine levels in pregnancy among women who take pre-
natal multivitamins [8]. Also a recent prospective study
shows that there is no difference in homocysteine levels at
midtrimester between women who later develop preec-
lampsia and those who do not [33].
As is the situation with NTDs, lack of folate deficiency by
current definitions in a non-pregnant woman may not
indicate that her folate intake is adequate for pregnancy.
This would especially be true for women with the C677T
MTHFR variant. Reexamination of the current definition
of what constitutes a normal biochemical result for folate
intake for women of child bearing age should be under-
taken to clarify this.
We suggest that the negative effects of the C677T MTHFR
variant are more likely to occur in early pregnancy before
women began taking prenatal vitamins because the
majority of our study participants took prenatal vitamins,
but only 35% took preconceptional supplements. We sus-
pect that reduced methylation interfering with cell prolif-
eration in the placenta as originally suggested by Eskes
(2000) [3].
In conclusion, using a retrospective case/control study, we
have found that women with unexplained MSAFP eleva-
tions who have complications in later pregnancy are more
likely to have the C677T MTHFR allele. Our resultsdo not
suggest that C677T MTHFR predisposes a woman to hav-
ing an elevation of MSAFP level (as we did not compare
the C677T MTHFR frequency in women with and without
elevated MSAFP), but having one or more copies of this
variant predisposes such screen positive women to having
complications in later gestation. It remains to be seen if
other risk factors can be identified which can more accu-
rately define this high risk group.
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